Ask AI
ProCE Banner Series

Decoding Transformative Advances in Hematologic Diseases: Conference-to-Clinic Insights for Winter 2026

Join us for live, interactive webinars to learn from experts as they discuss the management of patients with different hematologic diseases based on the latest available evidence. Full details on the available topics are provided below.

  AAPA
  | ACPE
  | AMA
  | AMA
  | ANCC
Who Should Attend

This activity is intended for healthcare professionals who care for patients with malignant or nonmalignant hematologic disorders.

All Events

Decoding Transformative Advances in Hematologic Diseases: Conference-to-Clinic Insights for Winter 2026

Upcoming Events

January

24

2026

9:30 AM - 2:40 PM Eastern Time (ET)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?

Goal Statement
This activity aims to improve learners’ knowledge, confidence, and competence at applying emerging clinical data and expert recommendations to optimally integrate menin inhibitors into treatment pathways for eligible patients with acute myeloid leukemia. 

Target Audience
This educational activity is intended for hematologists, medical oncologists, and other healthcare professionals who care for patients with acute myeloid leukemia. 

Learning Objectives
Upon completion of this event, participants should be able to:

  • Educate patients and colleagues on the mechanisms of action for menin inhibitors and the clinical rationale for inhibiting menin in AML
  • Plan individualized treatments leveraging approved or investigational menin inhibitors for patients with relapsed/refractory AML harboring KMT2A rearrangements or NPM1 mutations based on the latest evidence, expert recommendations, and patient-/disease-specific factors
  • Apply evidence-based strategies to mitigate and manage differentiation syndrome related to menin inhibitors in patients with AML

AL Amyloidosis: Transformative Advances and the Future of Personalized Care—Insights From the 2025 Hematology Meeting

Goal Statement
The activity aims to improve learner's knowledge, competence, and confidence in the multidisciplinary diagnosis and management of AL amyloidosis by integrating current evidence and emerging therapies. 

Target Audience
This educational activity is intended for hematologists and other healthcare professionals who care for patients with AL amyloidosis. 

Learning Objectives
Upon completion of this event, participants should be able to:

  • Demonstrate the ability to recognize the early signs and symptoms of AL amyloidosis
  • Analyze the efficacy and safety profiles of novel therapies in AL amyloidosis management
  • Differentiate between treatment options for advanced or relapsed AL amyloidosis patients
  • Apply evidence-based strategies to manage treatment-related toxicities to optimize patient outcomes
  • Construct a comprehensive, multidisciplinary care approaches that enhance patient-centered care

Addressing Challenges and Implementing Care Strategies to Optimize BCMA Bispecific Antibody Therapy in RRMM: Expert Insights, Patient Resources, and Adaptive Decision Support

Goal Statement
This activity aims to improve learners’ knowledge, confidence, and performance in initiating, managing, and coordinating care with BCMA bispecific antibodies for patients with RRMM. 

Target Audience
This activity is intended for hematologists/oncologists, oncology nurses and nurse practitioners, physician associates, pharmacists and other healthcare professionals involved in the care and treatment of patients with RRMM.

Emphasis will be placed on AE mitigation, transitions between academic and community care, and integration of patient-centered strategies to improve treatment continuity.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Interpret pivotal clinical trial data on BCMA bispecific antibodies, including efficacy, safety, and use in earlier lines of therapy.
  • Apply evidence-based strategies to initiate BCMA BsAb therapy and monitor for key adverse events (eg, CRS, ICANS, infections) across diverse practice settings.
  • Design multidisciplinary care coordination strategies to support therapy adherence and treatment continuation in patients transitioning from academic to community settings.
  • Integrate patient education and shared decision-making tools to align treatment with patient goals and improve persistence.

Accreditation

A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


AL Amyloidosis: Transformative Advances and the Future of Personalized Care—Insights From the 2025 Hematology Meeting

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through Clinical Care Options, LLC dba Decera Clinical Education's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC dba Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


Addressing Challenges and Implementing Care Strategies to Optimize BCMA Bispecific Antibody Therapy in RRMM: Expert Insights, Patient Resources, and Adaptive Decision Support

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC dba Decera Clinical Education and Smart Patients. Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-9999-26-053-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through Clinical Care Options, LLC dba Decera Clinical Education's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC dba Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

IPCE Credit Designation

A logo for a credit companyAI-generated content may be incorrect.

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

AL Amyloidosis: Transformative Advances and the Future of Personalized Care—Insights From the 2025 Hematology Meeting

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

Addressing Challenges and Implementing Care Strategies to Optimize BCMA Bispecific Antibody Therapy in RRMM: Expert Insights, Patient Resources, and Adaptive Decision Support

Provided by Clinical Care Options, LLC dba Decera Clinical Education, in partnership with Smart Patients.

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?

Supported by educational grants from Johnson & Johnson, Kura Oncology, Inc. and Syndax Pharmaceuticals, Inc.

AL Amyloidosis: Transformative Advances and the Future of Personalized Care—Insights From the 2025 Hematology Meeting

Supported by an educational grant from Alexion Pharmaceuticals. 

Addressing Challenges and Implementing Care Strategies to Optimize BCMA Bispecific Antibody Therapy in RRMM: Expert Insights, Patient Resources, and Adaptive Decision Support

Supported by an educational grant from Pfizer Inc.

Johnson & Johnson

Kura Oncology, Inc.

Syndax Pharmaceuticals, Inc.

Alexion Pharmaceuticals

Pfizer Inc.

Partners

Smart Patients

ProCE Banner

For customer support please click here.

Mailing Address:

 

Decera Clinical
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191